SCHEMBL4893743

SCHEMBL4893743

Cc1c(C(=O)O)cn(C)c1-c1ccccc1OC(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD11B1 P28845 1/20 0.44
DHODH Q02127 1/20 0.42
SCN9A Q15858 7/20 0.41
FFAR4 Q5NUL3 1/20 0.41
FABP4 P15090 1/20 0.40
FABP5 Q01469 1/20 0.40
RORC P51449 1/20 0.40
EP300 Q09472 1/20 0.40
HTT P42858 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4888733 0.82 BRD4 (0.50) ALDH1A1
SCHEMBL4783866 0.81 IRAK4 (0.43) ALDH1A1L3MBTL1
SCHEMBL2025180 0.81 TAS2R14 (0.47) ALDH1A1HSD11B1DHODHSCN9A
SCHEMBL4638610 0.79 PTGER1 (0.63) L3MBTL1DHODHRXRARXRBRXRG
SCHEMBL28500487 0.79 PTGER1 (0.59) ALDH1A1L3MBTL1HSD11B1DHODHSCN9A
SCHEMBL4892927 0.78 MYC (0.49) ALDH1A1L3MBTL1
SCHEMBL4639715 0.78 PTPN11 (0.46) ALDH1A1HTT
SCHEMBL2441786 0.77 NR3C2 (0.60) ALDH1A1RORCKCNK3KCNK9
SCHEMBL240363 0.76 FABP4 (0.49) ALDH1A1L3MBTL1DHODHSCN9AFFAR4
SCHEMBL4895914 0.76 MYC (0.42) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US claimed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885L3MBTL1 4875/4885HSD11B1 1982/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885L3MBTL1 4875/4885HSD11B1 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.